Valneva

Tweet this page
<
2020
2021
2022
2023
2024
>
Registration as it was on 17 Jan 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

100,000€ - 199,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

1 Fte (1)

Lobbyists with EP accreditation

0

High-level Commission meetings

2

Lobbying Costs over the years

  • Info

    Valneva

    EU Transparency Register

    116284040570-75 First registered on 04 Dec 2020

    Goals / Remit

    Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. The Company has several vaccines in development including vaccines against Lyme diseaseand chikungunya (the latter having received approval by US FDA in 2023). Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.

    Main EU files targeted

    Given Valneva’s experience in emerging diseases, the company’s business is actually or potentially affected by most of the policies related to Public Health, Research and Innovation. More specifically: Horizon Europe (Horizon 2020), EU4Health, Cross Border Health Threats Regulation, Pharmaceutical Strategy, New Industrial Strategy for Europe, Union Civil Protection Mechanism, HERA, EU FAB, European Critical Medicines Alliance.

    Address

    Head Office
    6 rue Alain Bombard
    Saint-Herblain 44800
    FRANCE
    EU Office
    Campus Vienna Biocenter 3
    Wien 1030
    AUSTRIA

    Website

  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    100%1

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    Valneva created in 2023 a Government Affairs function, albeit with only one person in charge for global activities and also acting for Europe. This position is therefore supported on EU policy affairs by several members of the team are overseeing the activities on ad hoc basis.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Vaccines Europe
    France Biotech
    Pharmig - Verband der pharmazeutischen Industrie Österreichs
    ÖVIH - Österreichischer Verband der Impfstoffhersteller
    WKÖ - Austrian Federal Economic Chamber
    Industriellenvereinigung (Vereinigung der Österreichischen Industrie)
    Signatary of UN Global Compact
    LIF - Läkemedelsindustriföreningens
    LEEM - Les Entreprises du Médicament
    ABPI UK - The Association of the British Pharmaceutical Industry
    Royal Society of Biology (UK)
    Biotechnology Innovation Organization (BIO, USA)
    Adult Vaccine Access Coalition (AVAC, USA)
    Medical Countermeasures Coalition (MC2, USA)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    100,000€ - 199,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    fipra international srl 50,000€ - 99,999€

    Intermediaries for current year

    Name
    fipra international srl

    Closed year Costs

    100,000€ - 199,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    Starting shot for vaccines. Early lessons from the ups and downs of COVID-19 immunisation roll-out(s) - in cooperation with European Health Forum Gastein (2021)
    "Outbreak Diseases: a sudden risk, a constant threat” - Event in the European Parliament to address preparedness for outbreak diseases.

    Other activities

    None declared

  • Meetings

    Meetings

    2 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 13 Mar 2023 Location Brussels
      Subject Valneva updated HERA on their products available and in development.
      DG Health Emergency Preparedness and Response Authority
      Attending
      • Pierre Delsaux (Director-General)
    • Date 02 Mar 2021 Location Videoconference
      Subject Vaccine production
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
      Other Lobbyists
Download this datacard